Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma.

The oncologist - 3 Nov 2022

Franses Joseph W, Lim Mir, Burgoyne Adam M, Mody Kabir, Lennerz Jochen, Chang Jeremy, Imperial Robin, Dybel Stacey N, Dinh Thi M, Masannat Jude, Weipert Caroline M, Hsiehchen David

Abstract excerpt

Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to High-Throughput Nucleotide Sequencing

Share to Liver Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36103364
DOI: 10.1093/oncolo/oyac189
PMCID: PMC9632309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma.PMID 36103364Read ↗

Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.Semantic proximity Read ↗

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular CarcinomaSemantic proximity Read ↗

Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma.Semantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular CarcinomaSemantic proximity Read ↗

Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.Semantic proximity Read ↗

Exploring real-world concordance of tissue mutation burden (TMB) from blood and tissue in patients with solid tumorsSemantic proximity Read ↗

Plasma Circulating Tumor DNA Sequencing Reveals the Landscape of Acquired Mutations in Patients with Hepatocellular Carcinoma: a Potential Predictive Value in Liquid BiopsySemantic proximity Read ↗

DNA methylation fingerprint of hepatocellular carcinoma from tissue and liquid biopsiesSemantic proximity Read ↗

The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.Semantic proximity Read ↗

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shedSemantic proximity Read ↗

Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.Semantic proximity Read ↗

Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.